|
INNOVATIVE BIOINDUSTRies |
|
|
|
June 2020, 2nd |
FEATURE STORY ● Novartis snags EU nod for SMA gene therapy GENE THERAPY ● Precision Therapy for inherited retinal disease: at the forefront of genomic medicine DISRUPTIVE TECHNOLOGIES ● Cancer cell therapies: the clinical trial landscape ● IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine ● Fate Therapeutics announces FDA clearance of IND application for FT538, first CRISPR-edited, iPSC-derived cell therapy ● Antisense ATL1102 final phase II DMD results meet primary endpoint and exceed expectations on secondary endpoints INDUSTRIAL LANDSCAPE & AGREEMENTS ● Gilead Sciences and Arcus Biosciences establish 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies ● Merck to acquire Themis ● Alnylam announces US FDA has granted priority review of the Lumasiran NDA for the treatment of primary hyperoxaluria type I ● Orgenesis announces collaboration with Hospital Infantil Universitario Niño Jesús, Madrid ● Novasep and Lysogene announce their new collaboration for the development and production of GM1 gangliosidosis gene therapy product |
---|
|
|
|
|
GENE THERAPY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
" BRIEFING ON RNA TRIALS" is the tool you need. |
● A 220-page report detailing more than 160 clinical trials ● More than 100 RNA therapeutics (antisense oligonucleotides, RNAi/siRNA, microRNA, mRNA...) presented ● UPDATED FEB 2020 - €990,00 excl. VAT ● Click here to get sample pages ● Click here to get order form |
---|
|
"BRIEFING ON CAR-T CELLS TRIALS" is a dedicated tool that presents: |
● More than 140 new clinical trials registered between 01/01/2018 and 12/01/2019 ● For each clinical trial, a novel format enriched by relevant contextualisation and information selected by our experts ● Updated DEC 2019 ● Click here to get sample pages and click here to get the order form |
---|
|
|
|
|
|
---|
|